A tale of 2 COVID-19 trials: compassionate use vs. EUA
We all need hope this holiday season, but as an experienced physician, biostatistician, and research methodologist, it is my duty to share why the encouraging vaccine results reported by pharma companies in the last month must be applauded but interpreted with caution.
Pfizer/BioNTech and Moderna are both to be commended for successfully recruiting tens of thousands of subjects in a remarkably narrow window of time. As a clinical trialist who has …
